Prog Neuropsychopharmacol Biol Psychiatry 21, 69-102, (1997) Maurice, T., & Lockhart, B. P. View abstract in PubMed Post navigationPreviousPrevious post:Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain.NextNext post:SA4503, a novel cognitive enhancer with sigma1receptor agonist properties, facilitates NMDA receptor-dependent learning in mice.Related PostsAnavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical TrialSeptember 10, 2020Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Parkinson’s DiseaseAugust 19, 2020Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)July 6, 2020Anavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Rett SyndromeJuly 1, 2020
Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical TrialSeptember 10, 2020
Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Parkinson’s DiseaseAugust 19, 2020
Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)July 6, 2020
Anavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Rett SyndromeJuly 1, 2020
